IDIX—It doesn't seem to me that the IDX899 compound is considered and or appreciated by those covering IDIX when it comes to valuation.
I agree and I think there’s an explanation: Until recently, most investors thought GILD owned the HIV market lock, stock, and barrel. A corollary: these investors thought no company had a chance to gain any traction in HIV unless it was working directly with GILD. IDIX’s partner, GSK, was considered a hopeless also-ran in HIV.
These views appear to finally be softening to some degree. Most investors still think non-GILD HIV programs face long odds, but there’s a growing recognition, IMO, that other companies have a shot if they play their cards right. GSK’s program for the integrase inhibitor, ‘572, is case in point (#msg-52482079).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.